Publications by authors named "D Valpiani"
Background: The lack of scientific evidence regarding the effectiveness of 5-aminosalicylate in patients with Crohn's disease is in sharp contrast to its widespread use in clinical practice.
Aims: The aim of the study was to investigate the use of 5-aminosalicylate in patients with Crohn's disease as well as the disease course of a subgroup of patients who were treated with 5-aminosalicylate as maintenance monotherapy during the first year of disease.
Methods: In a European community-based inception cohort, 488 patients with Crohn's disease were followed from the time of their diagnosis.
Background: Inflammatory bowel disease (IBD) places a significant burden on health-care systems because of its chronicity and need for expensive therapies and surgery. With increasing use of biological therapies, contemporary data on IBD health-care costs are important for those responsible for allocating resources in Europe. To our knowledge, no prospective long-term analysis of the health-care costs of patients with IBD in the era of biologicals has been done in Europe.
View Article and Find Full Text PDFBackground And Aim: A definitive diagnosis of Crohn's disease (CD) or ulcerative colitis (UC) is not always possible, and a proportion of patients will be diagnosed as inflammatory bowel disease unclassified (IBDU). The aim of the study was to investigate the prognosis of patients initially diagnosed with IBDU and the disease course during the following 5 years.
Methods: The Epi-IBD study is a prospective population-based cohort of 1289 IBD patients diagnosed in centers across Europe.
Article Synopsis
- This study investigated the long-term outcomes of ulcerative colitis (UC) patients using a population-based cohort to understand the impact of modern treatments like biological therapy and immunomodulators over five years.
- Out of 717 patients tracked, 6% required colectomy, and 23% were hospitalized, with some patients showing disease progression or regression.
- Despite aggressive treatments, the overall disease outcomes (like colectomy rates) did not differ significantly from previous decades, but immunomodulators were linked to a lower risk of hospitalizations.